Overview
Kura Oncology reports Q3 2025 net loss of $74.1 mln, up from $54.4 mln in 2024
Collaboration revenue for Q3 2025 was $20.8 mln, compared to none in Q3 2024
Company's ziftomenib program under FDA Priority Review, PDUFA date set for Nov 30, 2025
Outlook
Kura Oncology expects FDA decision on ziftomenib by November 30, 2025
Company plans to present clinical data at ASH Annual Meeting in December 2025
Kura expects to fund operations into 2027 with current cash and collaboration payments
Result Drivers
MILESTONE PAYMENTS - Received two $30 mln milestone payments from Kyowa Kirin for KOMET-017 trial progress
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$20.75 mln
Q3 Net Income
-$74.11 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Kura Oncology Inc is $27.00, about 63.8% above its November 3 closing price of $9.77
Press Release: ID:nGNXlVrbQ
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
